drugset / Trial / NCT03887624

Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression.

NCT03887624

Phase 0 Completed 16 enrolled Zhejiang University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study evaluates the efficacy and safety of ethosuximide in the treatment of refractory depressive disorder in adults. Half of participants will receive ethosuximide and escitalopram in combination, while the other half will receive a placebo and escitalopram.

Timeline

Start
2019-05-21
Primary completion
2021-04-01
Completion
2021-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ethosuximide Small molecule 1000 mg Oral
Background Escitalopram Small molecule 20 mg Oral